AzTrials
AzTrials

Hepatocellular Carcinoma Non-resectablePhase 1NCT04592029

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

A Phase 1 study testing TACE combined with sintilimab and bevacizumab in people with Hepatocellular Carcinoma Non-resectable, run by Second Affiliated Hospital of Guangzhou Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hepatocellular Carcinoma Non-resectable
What is being tested?
TACE combined with sintilimab and bevacizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteChina
Study dates
21 Oct 2020to 17 Mar 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Intermediate or advanced (Barcelona Clinic Liver Cancer stage B or C) HCC with diagnosis confirmed by histology/cytology or clinically
  • Disease not amenable to curative therapies but amenable to TACE
  • At least one measurable untreated lesion
  • No prior systemic therapy for HCC
  • Child-Pugh score class 5-7
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Show all 9Show fewer
  • Adequate organ and hematologic function
  • Life expectancy of at least 3 months
  • For women of childbearing potential and for men: agreement to remain abstinent

Who cannot join

  • Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Diffuse HCC
  • Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or upper mesenteric vein
  • Inferior vena cava tumor thrombus
  • Metastatic disease that involves major airways or blood vessels
  • Symptomatic, untreated or progressing central nervous system metastasis
Show all 34Show fewer
  • Uncontrolled tumor-related pain
  • Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC
  • Treatment with systemic immunostimulatory agents
  • Use of herbal therapies or traditional Chinese medicines with anti-cancer activity within 2 weeks
  • History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
  • Uncontrolled ascites, hydrothorax or pericardial effusion
  • Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment
  • Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring blood infusion, endoscopic or surgical intervention within 3 months
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
  • History of gastrointestinal (GI) perforation and/or fistula in the past 6 months
  • history of GI obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection, complicated by chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea
  • History of hepatic encephalopathy
  • History of organ and stem cell transplantation
  • Long-term daily treatment with a non-steroidal anti-inflammatory drug (NSAID)
  • Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10 mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea symptoms such as asthma and chronic obstructive pulmonary disease is allowed
  • History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Active tuberculosis
  • Active severe infection; use of antibiotics within 2 weeks prior to injection of sintilimab
  • Autoimmune disease or immune deficiency
  • Inadequately controlled hypertension; history of hypertensive crisis or hypertensive encephalopathy
  • Bleeding diathesis or significant coagulopathy
  • Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
  • underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks; non-recovery from side effects of these procedure
  • History of venous thromboembolism in the past 6 months, but implantable IV ports or catheter-derived thrombosis, superficial venous thrombosis, or thrombosis after conventional anticoagulant therapy are excluded
  • Current or recent use of aspirin or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol
  • uncontrolled metabolic disorder, non-malignant organ or systemic disease or secondary carcinomatous reaction, with high medical risk and/or uncertainty of life expectancy evaluation
  • Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study
  • Female patients who are pregnancy or breastfeeding

Trial locations and contacts

1 site in 1 country.

China1 site

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510260

Other trials in China

About this study

Official title: Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study

This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).

Read the detailed description

This is a Phase Ib study to evaluate the safety and efficacy of TACE combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced HCC.

36-39 subjects with unresectable intermediate or advanced HCC will be enrolled in the study.

This study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety evaluation. Then, sintilimab 200mg/kg IV. every three weeks (q3w) + the select specific dose of bevacizumab 7.5mg/kg (group 1) or 15mg/kg (group2) IV q3w, expand to 36 patients (18 patients each group) for the further safety and efficacy study.

Sintilimab and bevacizumab will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated based on the evaluation of follow-up laboratory and imaging examination. And the study treatment of sintilimab and bevacizumab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.

Being tested
TACE combined with sintilimab and bevacizumab

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TACE combined with sintilimab and bevacizumabDrug

    Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.

Study groups in NCT04592029
Study groupRoleWhat they receive
TACE-Sin-BevExperimentalTACE combined with sintilimab and bevacizumab.
Receives: Drug: TACE combined with sintilimab and bevacizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse Events (AEs)

    Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.

    Measured: 24 months

  2. Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).

    The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.

    Measured: 24 months

Secondary outcomes (8)

  1. Overall survival (OS)

    The time from initiation of treatment until the date of death from any cause.

    Measured: 24 months

  2. Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST.

    The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).

    Measured: 24 months

  3. Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST.

    The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).

    Measured: 24 months

  4. Duration of response (DOR) assessed by investigators according to RECIST 1.1 and irRECIST.

    The time from the first occurrence of a documented objective response to disease progression (PD) or death.

    Measured: 24 months

  5. PFS assessed by investigators according to Modified RECIST (mRECIST).

    The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.

    Measured: 24 months

  6. ORR assessed by investigators according to mRECIST.

    The percentage of patients who had a best overall tumor response rating of CR or PR.

    Measured: 24 months

  7. DCR assessed by investigators according to mRECIST.

    The percentage of patients who had a tumor response rating of CR, PR, or SD.

    Measured: 24 months

  8. DOR assessed by investigators according to mRECIST.

    The time from the first occurrence of a documented objective response to PD or death.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2020
  2. Study start21 Oct 2020
  3. Primary completion7 Feb 2023
  4. Study completion17 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04592029
Sponsor's protocol ID
MIIR-02
Status last verified
Aug 2026
First submitted
13 Oct 2020
Last updated
18 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TACE combined with sintilimab and bevacizumab in people with Hepatocellular Carcinoma Non-resectable, run by Second Affiliated Hospital of Guangzhou Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse Events (AEs) (time frame: 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04592029.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in